New Delhi, May 3 (PTI) Drug firm Lupin on Friday said it has launched its first biosimilar product in Canada.

The company has introduced Rymti through its partner Sandoz Canada, the Mumbai-based drug maker said in a statement.

Also Read | Coal Miners Day 2024 Date in India: Know History and Significance of the Day That Highlights the Efforts of Coal Miners.

Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents.

Rymti is approved for all therapeutic indications of the reference product Enbrel, Lupin stated.

Also Read | World Press Freedom Day 2024 Date, History and Significance: A Day To Remind Us of the Importance and the Fundamental Principles of Press Freedom.

"With this important milestone, we continue to advance healthcare accessibility and affordability for patients in Canada," Lupin CEO Vinita Gupta said.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)